- patients who at the time of admission require hospitalization and / or supplemental oxygen. - known history of allergy to ivermectin. - known medical history of liver disease. - belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. - the following comorbidities: - immunosuppression or hiv. - acute or chronic kidney failure. - current neoplasia. - currently use of warfarin, erdafitinib, or quinidine. - have received vaccination for sars-cov-2. - ivermectin consumption prior to inclusion in the research protocol. - the patient does not accept the conditions of home care and monitoring. - the patient desists from participating in the study. - women in pregnancy or breastfeeding.

- patients who at the time of admission require hospitalization and / or supplemental oxygen. - known history of allergy to ivermectin. - known medical history of liver disease. - belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. - the following comorbidities: - immunosuppression or hiv. - acute or chronic kidney failure. - current neoplasia. - currently use of warfarin, erdafitinib, or quinidine. - have received vaccination for sars-cov-2. - ivermectin consumption prior to inclusion in the research protocol. - the patient does not accept the conditions of home care and monitoring. - the patient desists from participating in the study. - women in pregnancy or breastfeeding.